Journal
LABORATORY INVESTIGATION
Volume 92, Issue 9, Pages 1310-1317Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/labinvest.2012.87
Keywords
DnaJB6; hsa-miR-632
Categories
Funding
- USPHS [CA140472, CA138850]
- American Medical Association
- Mayer Mitchell Award for Excellence in Cancer Research
Ask authors/readers for more resources
DNAJB6 is a constitutively expressed member of the HSP40 family. It has been described as a negative regulator of breast tumor progression and a regulator of epithelial phenotype. Expression of DNAJB6 is reported to be compromised with tumor progression. However, factors responsible for its downregulation are still undefined. We used a knowledge-based screen for identifying miRNAs capable of targeting DNAJB6. In this work, we present our findings that hsa-miR-632 (miR-632) targets the coding region of DNAJB6. Invasive and metastatic breast cancer cells express high levels of miR-632 compared with mammary epithelial cells. Analysis of RNA from breast tumor specimens reveals inverse expression patterns of DNAJB6 transcript and miR-632. In response to exogenous miR-632 expression, DNAJB6 protein levels are downregulated and the resultant cell population shows significantly increased invasive ability. Silencing endogenous miR-632 abrogates invasive ability of breast cancer cells and promotes epithelial like characteristics noted by E-cadherin expression with concomitant decrease in mesenchymal markers such as Zeb2 and Slug. Thus, miR-632 is a potentially important epigenetic regulator of DNAJB6, which contributes to the downregulation of DNAJB6 and plays a supportive role in malignant progression. Laboratory Investigation (2012) 92, 1310-1317; doi:10.1038/labinvest.2012.87; published online 18 June 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available